摘要
变态反应(过敏症)是指机体对某些抗原初次应答后,再次接触相同抗原刺激时,产生以机体生理功能紊乱或组织损伤为主的一种特异性免疫应答。吲哚胺-2,3双加氧酶(indoleamine 2,3 dioxygenase,IDO)既是细胞内催化色氨酸分子沿犬尿酸途径进行分解代谢的限速酶,也是一种重要的免疫调节酶。越来越多的研究表明,免疫耐受机制缺陷在变应性疾病中扮演着重要的角色,而抗原递呈细胞(APC)如树突状细胞(DC)表达的IDO可通过多种机制诱导机体产生免疫耐受。因此,通过增加DC表达IDO而诱导免疫耐受,有望成为治疗支气管哮喘、变应性鼻炎和特应性皮炎的新靶点。
Allergy (allergic disease) is an antigen-specific immune response, characteristic of physiological dysfunction or tissue injury. Indoleamine 2,3 dioxygenase (IDO) is recognized as an enzyme for both rate-limiting in the kynurenine-mediated tryptophan metabolism and natural immune regulation. Accumulating data suggest an essential role of defects in the mechanism of immune tolerance in allergic diseases. The expression of IDO by antigen-presenting cell (APC), such as dendritic cell (DC), can induce immune tolerance through multiple mechanisms. Therefore, it is promising to induce immune tolerance via upregulating IDO in DC for the treatment of bronchial asthma, allergic rhinitis, and atopic dermatitis.
出处
《中华哮喘杂志（电子版）》
CAS
2013年第1期53-57,共5页
Chinese Journal of Asthma(Electronic Version)
基金
国家自然科学基金(81170018)
江苏省医学重点人才项目(RC2011066)
江苏省333高层次人才培养工程(201115)
江苏省高校自然科学研究项目(11KJB320008)
江苏省高校优势学科建设工程(JX10231801)
江苏省卫生国际交流支撑计划(201235)
